Development of tinea corporis in a Japanese patient with atopic dermatitis under treatment with upadacitinib in a real‐world clinical setting: Possible contribution of the suppression of Th17
We present a rare case of a patient with AD who developed tinea corporis during upadacitinib treatment in a real‐world clinical setting. We hypothesized that the suppressive effect of Th17 immunity by upadacitinib possibly has contributed to the development of tinea corporis.
Main Authors: | Akihiko Uchiyama, Sei‐ichiro Motegi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Journal of Cutaneous Immunology and Allergy |
Online Access: | https://doi.org/10.1002/cia2.12258 |
Similar Items
-
Effectiveness of upadacitinib in Japanese patients with prurigo‐type atopic dermatitis: Four cases report
by: Keiji Kosaka, et al.
Published: (2023-12-01) -
TRICHOPHYTON INTERDIGITALE CAUSING SEVERE TINEA CORPORIS AND TINEA CRURIS ET CORPORIS
by: Seeba Hussain
Published: (2023-06-01) -
Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review
by: Alok Kumar Sahoo, et al.
Published: (2016-01-01) -
Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience
by: Chisako Fujiwara, et al.
Published: (2023-06-01) -
Characteristic of Tinea Cruris and/or Tinea Corporis in Ciamis District Hospital, West Java
by: Wulan Yuwita, et al.
Published: (2016-10-01)